Prevalence of BRCA1 and BRCA2 pathogenic sequence variants in ovarian cancer patients in the Gulf region: the PREDICT study

Fathi Azribi, Ehab Abdou, Emad Dawoud, Mohamed Ashour, Amgad Kamal, Mohamed Al Sayed, Ikram Burney, Fathi Azribi, Ehab Abdou, Emad Dawoud, Mohamed Ashour, Amgad Kamal, Mohamed Al Sayed, Ikram Burney

Abstract

Background: Patients with pathogenic sequence variants (PSVs) in BRCA1/BRCA2 are at high risk of developing ovarian cancer (OC). However, genetic testing for BRCA1/BRCA2 PSVs is still not a routine practice in the Middle East. With the lack of epidemiological studies in the region, we aim to describe the prevalence of BRCA1/BRCA2 PSVs in patients with OC across different countries in the Gulf region.

Methods: The PREDICT study was an observational, prospective, epidemiological study, which consecutively recruited women with ovarian, primary peritoneal, and fallopian tube cancers from the following Gulf countries over the period from July 2017 to July 2019; United Arab Emirates (UAE), Kuwait, and Oman. The study was approved by the local ethics committee of participating centers. The BRCA1/BRCA2 PSVs were assessed by tissue genetic testing using next-generation sequencing (NGS).

Results: A total of 105 women were included with a median age at diagnosis of 52 years (IQR 44.5 - 61.0). Nearly 11.4% of patients reported a family history of ovarian or breast cancer, while 4.7% of patients reported a family history of other cancers. Most of the patients (70.3%) had advanced disease (FIGO stage III/IV) at presentation. Eighty-eight patients (84%) were successfully tested for somatic BRCA1/BRCA2 PSVs. Fifteen patients (17%) were found to have PSVs in either BRCA1, BRCA2, or both genes; of them, 10 patients (11.2%) had BRCA1 somatic PSVs alone, eight patients (9.1%) had BRCA2 somatic PSVs, while three patients (2.9%) had both PSVs. Five patients with BRCA1/BRCA2 somatic PSVs had germline PSVs tests, and three of them tested positive. Concerning treatment, 87.6% of patients received perioperative chemotherapy and 6.6% as first-line palliative chemotherapy. Eighty-seven (82.9%) patients underwent debulking surgery, with no residual disease in 42.5% of patients.

Conclusion: Our study showed that the prevalence of BRCA1/BRCA2 somatic PSVs in patients with OC is higher than the reported global figures (2-8%). However, more studies are warranted to further elucidate the prevalence of BRCA1/BRCA2 somatic and germline PSVs, as well as other relevant genetic alterations, to better understand their impact on OC patient outcomes in Gulf countries.

Trial registration: NCT03082976 .

Keywords: Cancer genetics; Epidemiology; Gynaecological oncology.

Conflict of interest statement

Amgad Kamal and Mohamed Alsayed work for AstraZeneca; however, there is no conflict of interest. Dr. Fathi Azribi has received honoraria for Advisory board, as a speaker and travel, from AstraZeneca, Pfizer, Novartis, BMS, Amgen, and MSD. The rest of the authors declare that they have no conflict of interest.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Proportion of patients with BRCA1, BRCA2 PSVs

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492.
    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram IBF. Global Cancer Observatory: Cancer Today. 2018.
    1. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Women's Health. 2019;11:287–299. doi: 10.2147/IJWH.S197604.
    1. Coburn SB, Bray F, Sherman ME, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140:2451–2460. doi: 10.1002/ijc.30676.
    1. SEER Cancer stat facts: ovarian cancer. National Cancer Institute. .
    1. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer. 2001;85:944–952. doi: 10.1054/bjoc.2001.2030.
    1. Ortashi O. Gynecological cancer services in Arab countries: present scenario, problems and suggested solutions. Asian Pac J Cancer Prev. 2013;14:2147–2150. doi: 10.7314/APJCP.2013.14.3.2147.
    1. Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3:138–150. doi: 10.1016/j.molonc.2009.02.001.
    1. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015;313:1347–1361. doi: 10.1001/jama.2014.5985.
    1. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian Cancer study group. J Clin Oncol. 2012;30:2654–2663. doi: 10.1200/JCO.2011.39.8545.
    1. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–2416. doi: 10.1001/JAMA.2017.7112.
    1. John EM, Miron A, Gong G, Phipps AI, Felberg A, Li FP, et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA. 2007;298:2869–2876. doi: 10.1001/jama.298.24.2869.
    1. Hennessy BTJ, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28:3570–3576. doi: 10.1200/JCO.2009.27.2997.
    1. Li W, Shao D, Li L, Wu M, Ma S, Tan X, et al. Germline and somatic mutations of multi-gene panel in Chinese patients with epithelial ovarian cancer: a prospective cohort study. J Ovarian Res. 2019;12:80. doi: 10.1186/s13048-019-0560-y.
    1. Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer. 2010;20:704–716. doi: 10.1111/IGC.0b013e3181dbd1a5.
    1. Nassar HR, Sallam YA, Darwish T, Elbassuiony MA. Clinicopathological, Epidemiologic Characteristics and Treatment Outcomes of Ovarian Cancer Patients at NCI, Cairo University. EC Cancer. 2016:2(3):106–20.
    1. Abdulrashid K, Alhussaini N, Ahmed W, Thalib L. Prevalence of BRCA mutations among hereditary breast and/or ovarian cancer patients in Arab countries: systematic review and meta-analysis. BMC Cancer. 2019;19:256. doi: 10.1186/s12885-019-5463-1.
    1. Ashour M, Shafik HE. Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome. Cancer Manag Res. 2019;11:6275–6284. doi: 10.2147/CMAR.S206817.
    1. Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615. doi: 10.1038/nature10166.
    1. McAlpine JN, Porter H, Köbel M, Nelson BH, Prentice LM, Kalloger SE, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012;25:740–750. doi: 10.1038/modpathol.2011.211.
    1. Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, et al. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget. 2016;7:1076–1083. doi: 10.18632/oncotarget.6834.
    1. Koczkowska M, Zuk M, Gorczynski A, Ratajska M, Lewandowska M, Biernat W, et al. Detection of somatic BRCA1/2 mutations in ovarian cancer – next-generation sequencing analysis of 100 cases. Cancer Med. 2016;5:1640–1646. doi: 10.1002/cam4.748.
    1. Chao A, Chang T, Lapke N, Jung S, Chi P, Chen C, et al. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer. Oncotarget. 2016;7:85529–85541. doi: 10.18632/oncotarget.13456.
    1. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807–2816. doi: 10.1002/cncr.21536.
    1. Heintz A, Odicino F, Maisonneuve P, Quinn M, Benedet J, Creasman W, et al. Carcinoma of the ovary. Int J Gynecol Obstet. 2006;95:S161–S192. doi: 10.1016/S0020-7292(06)60033-7.
    1. Keyver-Paik M-D, Abramian A, Domröse C, Döser A, Höller T, Friedrich M, et al. Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer. J Cancer Res Clin Oncol. 2016;142:481–487. doi: 10.1007/s00432-015-2055-6.
    1. Stratton JF, Pharoah P, Smith SK, Easton D, Ponder BA. A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol. 1998;105:493–499. doi: 10.1111/j.1471-0528.1998.tb10148.x.
    1. Easton D, Peto J. The contribution of inherited predisposition to cancer incidence. Cancer Surv. 1990;9:395–416.
    1. Negri E, Pelucchi C, Franceschi S, Montella M, Conti E, Dal Maso L, et al. Family history of cancer and risk of ovarian cancer. Eur J Cancer. 2003;39:505–510. doi: 10.1016/S0959-8049(02)00743-8.
    1. Bu R, Siraj AK, Al-Obaisi KAS, Beg S, Al Hazmi M, Ajarim D, et al. Identification of novel BRCA founder mutations in middle eastern breast cancer patients using capture and sanger sequencing analysis. Int J Cancer. 2016;139:1091–1097. doi: 10.1002/ijc.30143.
    1. Siraj AK, Bu R, Iqbal K, Siraj N, Al-Haqawi W, Al-Badawi IA, et al. Prevalence, spectrum, and founder effect of BRCA1 and BRCA2 mutations in epithelial ovarian cancer from the Middle East. Hum Mutat. 2019;40:729–733. doi: 10.1002/humu.23736.
    1. Altinoz A, Al Ameri M, Qureshi W, Boush N, Nair SC, Abdel-Aziz A. Clinicopathological characteristics of gene-positive breast cancer in the United Arab Emirates. Breast. 2020;53:119–124. doi: 10.1016/j.breast.2020.07.005.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe